Roundtable video conference regarding Leronlimab and RANTES with Dr. Bruce Patterson of IncellDX.
Leronlimab is a humanized monoclonal IgG antibody that blocks CCR5. CCR5 receptor and RANTES complex then transduces a signal by increasing the intracellular calcium ion level and activating the enzyme GTPases.
Leronlimab was originally developed for HIV and worked by blocking the CCR5 receptor and stopping the calcium signaling.
By blocking the CCR5 receptor on leukocytes, the idea with Leronlimab is that you are blocking the transmission of the chemokine signal from RANTES, thus preventing the migration of more immune cells to attenuate a cytokine storm.
It is also believed that Leronlimab’s other effect is the polarization of macrophages from pro-inflammatory to anti-inflammatory phenotypes.
This roundtable discussion with Drs. Patterson, Hansen, and Yogendra go over recent updates regarding Leronlimab, RANTES, new clinical trials and data, and why Leronlimab might be the game changer to treat severe COVID-19 infections.
Coronavirus Live Question Answer (Session – 6) – Dr. Mike Hansen (Pulmonologist) & Dr. Yo (Anesthesiologist)
Today’s Guest Speaker is:
Dr. Bruce Patterson
CEO of IncellDx in San Carlos and also a Top Virologist.
Dr. Mike Hansen, MD
Internal Medicine | Pulmonary Disease | Critical Care Medicine
Please subscribe to Dr. Mike Hansen YouTube channel and press the bell icon:
Follow Dr. Mike Hansen’s Instagram Account:
Follow Dr. Mike Hansen’s Facebook:
Dr. Yo (Ram Yogendra)
Board-certified Anesthesiologist (American Board of Anesthesiology)
Specializing in physiology and Biometrics in sports and fitness
Please subscribe to Dr. Yo YouTube channel and press the bell icon: